Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | OSBP | P22059 | 1/20 | 0.30 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2424472 | 0.88 | OSBP (0.34) | LMNAMEN1CYP3A4ALOX15MAPK1 | |
| SCHEMBL12324739 | 0.81 | NR3C1 (0.33) | LMNAOSBPOSBP2 | |
| SCHEMBL2425327 | 0.81 | LMNA (0.41) | LMNACES2 | |
| SCHEMBL12324738 | 0.81 | LMNA (0.41) | LMNACES2 | |
| SCHEMBL2422520 | 0.74 | — | — | |
| SCHEMBL31178438 | 0.69 | USP2 (0.38) | LMNA | |
| SCHEMBL7546327 | 0.68 | — | — | |
| SCHEMBL7550977 | 0.67 | CYP3A4 (0.35) | LMNAMEN1CYP3A4ALOX15MAPK1 | |
| SCHEMBL7576227 | 0.66 | CYP3A4 (0.34) | LMNAMEN1CYP3A4ALOX15MAPK1 | |
| SCHEMBL7545401 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445732-B2 | Organic compounds | GIVAUDAN SA (CH) | 2013-05-21 | — | — | US | claimed |
| EP-2252674-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-09-07 | — | — | EP | claimed |
| US-20100331427-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-12-30 | — | — | US | claimed |
| EP-2252674-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-11-24 | — | — | EP | claimed |
| WO-2009100554-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2009-08-20 | — | — | WO | claimed |
| US-8445732-B2 | Organic compounds | GIVAUDAN SA (CH) | 2013-05-21 | — | — | US | disclosed |
| EP-2252674-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-09-07 | — | — | EP | disclosed |
| US-20100331427-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-12-30 | — | — | US | disclosed |
| EP-2252674-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009100554-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331427-A1 | Organic Compounds | C9, C5, CBR3 | LMNA 3019/4885MEN1 2813/4885CYP3A4 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.